|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||19.96 / 26.35|
Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium
Company Earns Outstanding Employer Distinction; Individual Employee Receives Patriot Award
Animal health and oncology deal activity is heating up in 2017.
Shares of Ariad Pharmaceuticals soared Monday after Japan's Takeda Pharmaceutical offered to buy the leukemia drug maker.
The Nikkei 225 closed with a gain for 2016, making a run of five consecutive higher year-end closes -- the first since the 1990 bubble.
The SEC has released correspondence between the agency and Valeant over concerns about its tax accounting and non-GAAP reporting measures.
Here's a technical look on how to trade some of the most active stocks on the market today.
Valeant shares fell Wednesday on news that talks with Takeda to take over Valeant's Salix unit have broken down.
Brad Loncar, CEO of Loncar Investment said don't throw in the towel on biotech stocks yet.
Biotech stocks are struggling this year, but investors should not throw in the towel on Amgen, Gilead, bluebird and Bellicum
Takeda Pharmaceuticals (TKPYY) CEO Christophe Weber said the company is exploring deals outside of Japan, particularly in the U.S.
Karyopharm announced study results in which its experimental drug selinexor demonstrated a 20% tumor response rate in multiple myeloma patients no longer responsive to four or five currently approved therapies.
Stocks inch higher by mid-afternoon Friday as Federal Reserve Chair Janet Yellen suggest the central bank could implement another rate hike this summer.
Shares of Valeant Pharmaceuticals jumped following last night's report by The Wall Street Journal saying that the company rejected a joint takeover approach from Takeda Pharmaceuticals and TGP Capital.
Takeda Pharmaceutical Company Limited ( TSE: 4502) today announced that the U.
Let's look back at the stock performance of biotech companies issuing the worst, most pandering press releases from January 2014.
Shares of Takeda Pharmaceutical (TKPYY) are down as the company said it would fight $6 billion in punitive damages imposed by a U.S. federal jury in a case alleging the drugmaker concealed cancer risks associated with its Actos diabetes drug,
Shares of Eli Lilly (LLY) may fall today after a jury ordered the company to pay $3 billion and Takeda (TKPYY) to pay $6 billion in punitive damages over allegations that they hid the cancer risks associated with the diabetes therapy Actos.
Drug companies Affymax and Takeda issue a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients.